KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Cvs Health (CVS) Gains from Sales and Divestitures (2017)

Cvs Health's Gains from Sales and Divestitures history spans 1 years, with the latest figure at $2.3 million for Q4 2017.

For the quarter ending Q4 2017, Gains from Sales and Divestitures changed N/A year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Dec 2017, changed N/A, and an annual FY2017 reading of $2.3 million, changed N/A over the prior year.
Gains from Sales and Divestitures for Q4 2017 was $2.3 million at Cvs Health.
The five-year high for Gains from Sales and Divestitures was $2.3 million in Q4 2017, with the low at $2.3 million in Q4 2017.